Dr. Ruben Mesa describes various tools used to better predict disease behavior, specifically symptoms, among polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis. Mesa lays out the overall survival rates based on data collected and what we’ve learned. Dr. Jorge Cortes discusses the scores or “median survival” and how they are used to calculate statistics for survival. Both help us understand the efficacy and limitations of these tools.
Produced in association with The University of Texas MD Anderson Cancer Center
Be the first to know about new programs and information with email alerts.
How early should a JAK2 inhibitor be prescribed for myelofibrosis or other myeloproliferative conditions? Approved and investigational JAK2 inhibitors are now being used by patients with more advanced and aggressive MPNs, but not as often in earlier stages. Watch now as Dr. Srdan Verstovsek gives his opinion on how JAK inhibitors should be used.